Regencell Bioscience (RGC) Stock Price, News & Analysis

Company Overview

Regencell Bioscience Holdings Limited is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges.

The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions. Regencell has also conducted research involving formulations for other health conditions, but its principal strategic focus has been on treatments for dementia and ADHD. These products remain investigational and are subject to clinical development and applicable regulatory requirements.

Regencell was established in 2014 and is based in Hong Kong, where it conducts its research and development activities. The company is led by Yat-Gai Au, who serves as its chief executive officer and has been associated with Regencell’s development since its early operations. Regencell Bioscience Holdings Limited trades on the Nasdaq Capital Market under the symbol RGC.

Key Stats

• Today's Range: $7.28 to $7.75
• 50-Day Range: $5.02 to $7.63
• 52-Week Range: $4.51 to $69.00
• Volume: 117,886 shs
• Average Volume: 134,592 shs
• Market Capitalization: $3.64 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Regencell Bioscience Stock Analysis - MarketRank™

Regencell Bioscience scored higher than 8% of companies evaluated by MarketBeat, and ranked 834th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Regencell Bioscience has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Regencell Bioscience has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Regencell Bioscience has a P/B Ratio of 735.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.14% of the float of Regencell Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Regencell Bioscience has a short interest ratio ("days to cover") of 7.29.

Change versus previous month

Short interest in Regencell Bioscience has recently decreased by 18.10%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Regencell Bioscience does not currently pay a dividend.

Dividend Growth

Regencell Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.33

News Sentiment

Regencell Bioscience has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Regencell Bioscience this week, compared to 4 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Regencell Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.00% of the stock of Regencell Bioscience is held by insiders.

Percentage Held by Institutions

0.13% of the stock of Regencell Bioscience is held by institutions.

Company Calendar

• Last Earnings: 10/07/2026
• Today: 10/10/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:RGC
• Previous Symbol: NASDAQ:RGC
• CIK: 1829667
• Web: regencellbioscience.com
• Phone: 852 2155 0823
• Fax: 852-2155-0853
• Employees: 10
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.01 per share
• Price / Book: 735.00

Miscellaneous

• Outstanding Shares: 495,880,000
• Free Float: 484,599,000
• Market Cap: $3.64 billion
• Optionable: N/A
• Beta: 1.18